Edition:
United Kingdom

Teligent Inc (TLGT.OQ)

TLGT.OQ on NASDAQ Stock Exchange Global Select Market

3.30USD
23 Jan 2018
Change (% chg)

$-0.10 (-2.94%)
Prev Close
$3.40
Open
$3.39
Day's High
$3.42
Day's Low
$3.29
Volume
67,473
Avg. Vol
152,714
52-wk High
$9.53
52-wk Low
$2.82

Chart for

About

Teligent, Inc. is a specialty generic pharmaceutical company. Under the Company's own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 16 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December... (more)

Overall

Beta: 1.56
Market Cap(Mil.): $379.08
Shares Outstanding(Mil.): 53.39
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.11 16.62
EPS (TTM): -- -- --
ROI: -- 14.89 10.61
ROE: -- 16.37 14.21

BRIEF-TELIGENT ANNOUNCES FDA GENERIC APPROVAL OF HYDROCORTISONE BUTYRATE LOTION 0.1%

* TELIGENT, INC. ANNOUNCES FIRST FDA GENERIC APPROVAL OF HYDROCORTISONE BUTYRATE LOTION 0.1%

22 Nov 2017

BRIEF-TELIGENT ANNOUNCES FDA APPROVAL OF ERYTHROMYCIN TOPICAL SOLUTION USP, 2%

* TELIGENT, INC. ANNOUNCES FDA APPROVAL OF ERYTHROMYCIN TOPICAL SOLUTION USP, 2%

21 Nov 2017

BRIEF-Teligent announces FDA approval of betamethasone dipropionate ointment usp (augmented), 0.05%​

* Announces FDA approval of betamethasone dipropionate ointment USP (augmented), 0.05%​

10 Nov 2017

BRIEF-Teligent posts Q3 qtrly ‍loss per share $0.12​

* Q3 earnings per share view $-0.01, revenue view $19.1 million -- Thomson Reuters I/B/E/S

06 Nov 2017

BRIEF-Teligent announces FDA approval of partnered ANDA for Desonide Lotion

* Teligent Inc announces FDA approval of partnered ANDA for Desonide Lotion, 0.05 pct

02 Oct 2017

BRIEF-Teligent Inc announces FDA approval of triamcinolone acetonide cream USP, 0.1%

* Teligent Inc announces FDA approval of triamcinolone Acetonide Cream USP, 0.1%

19 Sep 2017

BRIEF-Teligent reports FDA approval of clobetasol propionate cream USP

* Teligent Inc. Announces FDA approval of clobetasol propionate cream usp, 0.05 pct, emollient

22 Aug 2017

BRIEF-Teligent Q2 adjusted loss per share $0.01

* Teligent Inc says now anticipates gross margin of 47 percent to 50 percent for year ending December 31, 2017 Source text for Eikon: Further company coverage:

08 Aug 2017

Competitors

Earnings vs. Estimates